Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells

Imatinib mesylate is the leading compound to treat chronic myeloid leukemia (CML) and other cancers, through its inhibition of Bcr-Abl tyrosine kinases. However, resistance to imatinib develops frequently, particularly in late-stage disease and has necessitated the development of new Bcr-Abl inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Arvaniti, Katerina, Papadioti, Anastasia, Kinigopoulou, Maria, Theodorou, Vassiliki, Skobridis, Konstantinos, Tsiotis, Georgios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302748/
https://www.ncbi.nlm.nih.gov/pubmed/28250386
http://dx.doi.org/10.3390/proteomes2030363

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5302748/
https://www.ncbi.nlm.nih.gov/pubmed/28250386
http://dx.doi.org/10.3390/proteomes2030363

Ejemplares similares